Literature DB >> 29234968

A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013.

Phillip L Marotta1,2, Charlotte A McCullagh3,4.   

Abstract

Data at the individual-level provide evidence that opioid substitution treatment (OST) programs protect against mortality for opioid dependent populations. Prior research has not examined the merits of national implementation of opioid substitution programs for reducing mortality at the country-level. This study elucidates longitudinal associations between country-level implementation of opioid substitution treatment programs on mortality rates of drug related deaths (DRD) from 1995 to 2013 in 30 European nations. Cases of DRD were measured using National Definitions for each country from official sources of data. Preliminary analysis of dispersion of cases of DRD using means and variances justified use of the negative binomial regression model with a population offset. Year and country-level fixed effects negative binomial regression models investigated the association between years of implementation of methadone maintenance therapy (MMT), OST in prison, and high dose buprenorphine treatment (HDBT) implementation and mortality rates from drug related deaths after adjusting for unemployment rates, heroin seizures and per capita expenditures on health. Beta coefficients were converted to Incidence Rate Ratios (IRR) and standard errors bootstrapped using non-parametric methods to adjust for bias (SDbs). The mean mortality rate of DRD was 1.81 from 1995 to 2013. In adjusted models, each additional year of MMT (IRR = .61, SD = .04, p < .001; SDbs = .08, p < .001), prison OST (IRR = .90, SD = .01, p < .001; SDbs = .02, p < .001), and HDBT (IRR = .09, SD = .02, p < .001; SDbs = .02, p < .01) was significantly associated with lower rates of DRDs after adjusting for country and year fixed effects. Implementation of OST programs in the general population and in prison settings may have protected against mortality from drug use at the country-level in Europe from 1995 to 2013.

Entities:  

Keywords:  Heroin; Opioid substitution treatment; Overdose

Mesh:

Substances:

Year:  2017        PMID: 29234968      PMCID: PMC5997507          DOI: 10.1007/s10654-017-0342-z

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  73 in total

1.  The relationship between health care expenditure and health outcomes. Evidence and caveats for a causal link.

Authors:  John Nixon; Philippe Ulmann
Journal:  Eur J Health Econ       Date:  2006-03

2.  Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models.

Authors:  W Gardner; E P Mulvey; E C Shaw
Journal:  Psychol Bull       Date:  1995-11       Impact factor: 17.737

3.  One-year mortality rates following methadone treatment discharge.

Authors:  D A Zanis; G E Woody
Journal:  Drug Alcohol Depend       Date:  1998-11-01       Impact factor: 4.492

4.  Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico.

Authors:  Robert Heimer; Holly Catania; Robert G Newman; John Zambrano; Arlyn Brunet; Arturo Marti Ortiz
Journal:  Drug Alcohol Depend       Date:  2005-12-05       Impact factor: 4.492

5.  High prevalence of non-fatal overdose among people who inject drugs in Malaysia: Correlates of overdose and implications for overdose prevention from a cross-sectional study.

Authors:  Alexander R Bazazi; Alexei Zelenev; Jeannia J Fu; Ilias Yee; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2014-12-02

Review 6.  The Misuse of Prescription Opioids: A Threat for Europe?

Authors:  Jan van Amsterdam; Wim van den Brink
Journal:  Curr Drug Abuse Rev       Date:  2015

7.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Authors:  Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild Olsen; Shannon G Mitchell; Jerome H Jaffe
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

8.  Causes of death in a cohort treated for opioid dependence between 1985 and 2005.

Authors:  Louisa Degenhardt; Sarah Larney; Deborah Randall; Lucy Burns; Wayne Hall
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

9.  Supply control and harm reduction: lessons from the Australian heroin 'drought'.

Authors:  Don Weatherburn; Craig Jones; Karen Freeman; Toni Makkai
Journal:  Addiction       Date:  2003-01       Impact factor: 6.526

10.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16
View more
  4 in total

1.  Patients' Perspectives on Coming Off Opioid Agonist Treatment: A Qualitative Study.

Authors:  Christina Nehlin; Josefin Bäckström; Charlotte Wollert Brander; Caisa Öster
Journal:  Subst Abuse       Date:  2022-06-21

2.  From restrictive to more liberal: variations in moratlity among patients in opioid maintenance treament over a 12-year period.

Authors:  Anne Bukten; Marianne Riksheim Stavseth; Thomas Clasuen
Journal:  BMC Health Serv Res       Date:  2019-08-07       Impact factor: 2.655

3.  Objectives, design and main findings until 2020 from the Rotterdam Study.

Authors:  M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman
Journal:  Eur J Epidemiol       Date:  2020-05-04       Impact factor: 8.082

4.  Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.

Authors:  Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez
Journal:  Addiction       Date:  2021-12-04       Impact factor: 7.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.